Lidocaïne Accord (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilising the membrane and preventing the initiation and propagation of nerve impulses. This reversible blockade stops pain signals from reaching the brain, producing localized numbness.

The appropriate dose of Lidocaïne Accord is determined by the prescribing clinician based on the route of administration, patient weight, procedure type and safety limits. Exact dosing regimens are not disclosed here and must follow the prescriber’s order.

Safety data for lidocaine during pregnancy and lactation are limited. Use is generally reserved for situations where the benefit outweighs potential risk, and the decision should be made by the treating physician after evaluating maternal and fetal considerations.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Both lidocaine and bupivacaine are amide‑type local anesthetics, but lidocaine has a faster onset and shorter duration of action, making it suitable for short procedures. Bupivacaine provides longer lasting analgesia but carries a higher risk of cardiotoxicity at equivalent doses.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from direct sunlight, moisture and extreme temperature fluctuations. Ensure the container is sealed when not in use to maintain sterility.

Lidocaïne Accord is administered by a qualified healthcare professional via epidural, intramuscular or intravenous routes, depending on the clinical indication. The drug is injected as a sterile solution, and dosage is adjusted according to the specific procedure and patient factors.

Serious risks include allergic reactions such as anaphylaxis, cardiac arrhythmias or conduction disturbances, methemoglobinemia, and central nervous system toxicity leading to seizures. Immediate medical attention is required if any of these events occur.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, and individuals taking certain Class I antiarrhythmic drugs should avoid using Lidocaïne Accord unless a specialist determines that benefits outweigh risks.